Methods for prognosis, stratification and monitoring of the severity of coronavirus disease

In the present invention inventors used measured cytokine levels in serum of patients with COVID-19, at the time of hospital admission. Thereafter, inventors used a non-supervised bioinformatics approach to identify the cytokine combinations that represent a reliable biomarker of COVID-19-related severity and/or mortality. Briefly cytokine concentrations were measured at hospital admission in serum of symptomatic COVID-19 patients (N=115), classified at hospitalization into three respiratory severity groups: moderate severity with no need for mechanical ventilatory support (No-MVS), intermediate severity requiring mechanical ventilatory support (MVS) and critical severity requiring extracorporeal membrane oxygenation (ECMO). More specifically present invention relates to methods for prognosis and/or classification and/or stratification and/or monitoring of the pulmonary critical form of coronavirus disease and/or of critically severe coronavirus disease through comparison of specific cytokine combinations in a COVID-19 patient. The present invention also relates to a method of treating a coronavirus disease in a subject in need thereof by guiding a precision medicine approach through detection of specific cytokine profiles in a patient.

Keywords: Cytokine Signature, Covid19, Prognostic, Treatment Response
Patent Application number: EP21 305 526.2 on 21/04/2021 and PCT/EP2022/060457 on 20/04/2022
Publications:
J Allergy Clin Immunol 2021 Jun6 Dorgham et al. Distinct cytokine profiles associated with COVID-19 severity and mortality doi: 10.1016/j.jaci.2021.03.047. Epub 2021 Apr 22.

Reference:

BIO21080-D1

    Business Developper
    contact
    Pierre MAZOT
    Business Developer
    Patent filling date: 2021-04-21

    You might also be interested in